SecBot SecBot
SC TO-C ·Filed Sep 24, 2026

UTMD

UTAH MEDICAL PRODUCTS INC
MIXED
Impact 6/10
Horizonweeks Processed1mo ago SEC0001096906-26-001439
Tender offer communication
Actionable Insight ◆ Mixed

The tender offer provides a near-term catalyst for the stock price toward the $75 offer price, but the disclosed 12% revenue and 13% profit decline raises fundamental concerns. Monitor the proration level and expiration on October 7; a low take-up would signal weak shareholder conviction, while full subscription would reduce float significantly. Watch for any subsequent guidance updates or strategic announcements.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$74.18
T+0 close · Sep 24, 2026 · via day close
Latest settled
+0.07%
T+20 · $74.23 · next T+60 in 5w
Vs SPY
+1.54%
α at T+20
Latest observation
−1.99%
T+36 · FF3 residual α
  1. T+0 · Sep 25 $74.18entry
  2. T+1 · 7w ago +0.42%α +1.16% · $74.49
  3. T+5 · 7w ago −0.07%α +0.15% · $74.13
  4. T+20 · 25d ago +0.07%α +1.54% · $74.23
  5. T+36 · todayOpen
  6. T+60 · in 5w Pending
Loading chart...

Executive Summary

Utah Medical Products (UTMD) commenced an issuer tender offer to repurchase up to 650,000 shares at $75.00 per share, representing a 17% premium over the 12-month average closing price and a 21% premium over the 24-month average. The offer comes as the company disclosed that first-half 2026 sales and net profits declined 12% and 13% year-over-year, respectively. Management views the stock as undervalued and believes the buyback will enhance remaining shareholders' value, but the concurrent revenue and profit decline signals underlying operational weakness.

Key Financial Metrics

Deal Value
$48.8M
Premium
17%

Key Facts

  • UTMD offers to buy up to 650,000 shares at $75.00 per share, a 17% premium over the 12-month average closing price and a 21% premium over the 24-month average.
  • First-half 2026 sales declined 12% and net profits declined 13% versus the same period in 2025.
  • EBITDA for the most recent twelve months (last half of 2025 + first half of 2026) was $15,703,744.
  • The tender offer expires on October 7, 2026, unless extended.
  • The Board approved the offer but makes no recommendation to stockholders to tender or refrain.
  • CEO Kevin Cornwell states the stock is undervalued and would be fairly trading around $90 per share based on industry multiples.

Financial Impact

Up to $48.75 million in cash deployed if fully subscribed (650,000 shares × $75.00). First-half 2026 sales down 12% and net profits down 13% YoY.

revenuenet profitEBITDAshare countcash

Risk Factors

  • Revenue and profit declines may persist or worsen, undermining the buyback's value-enhancement thesis.
  • If too many shares are tendered, the company may prorate, leaving some shareholders with unsold shares and a post-offer price drop.
  • The offer does not have a minimum condition, so any number of shares may be purchased, but the company's cash position and credit facility could be strained if fully subscribed.

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC TO-C Filing (Primary)0001096906-26-001439
Document: 0001096906-26-001439-index-headers.html0001096906-26-001439
Document: 0001096906-26-001439-index.html0001096906-26-001439
Document: 0001096906-26-001439.txt0001096906-26-001439

Track record

11 reports on UTMD

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.45% at T+20 after the Apr 23, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $70.02 Now $72.36 +3.34% settles Dec 2
  2. Oct 29, 202618d ago Insider Buy Neutral 3/10 Entry $68.08 Now $72.36 +6.29% settles Nov 30
  3. Oct 29, 202618d ago SC TO-I/A Neutral 4/10 Entry $66.80 Now $72.36 +8.32% settles Nov 27
  4. Oct 22, 202625d ago 8-K Mixed 5/10 Entry $75.06 Now $72.36 −3.60% settles Nov 19
  5. Oct 5, 20266w ago SC TO-I/A Neutral 3/10 Entry $73.31 to $68.08 Now $72.36 −1.30% ▼ −7.14% −4.67% vs SPY
  6. Sep 25, 20267w ago SC TO-C Neutral 2/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
  7. Sep 24, 20267w ago SC TO-C Mixed 6/10 Viewing Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
  8. Sep 23, 20267w ago SC TO-I Mixed 5/10 Entry $74.75 to $75.06 Now $72.36 −3.20% ▲ +0.41% +0.83% vs SPY
  9. Aug 31, 202611w ago 8-K Bullish 5/10 Entry $71.13 to $74.95 Now $72.36 +1.73% ▲ +5.37% +5.56% vs SPY
  10. Jul 23, 202616w ago 8-K Bearish 7/10 Entry $64.18 to $71.42 Now $72.36 −12.75% ▼ −11.28% −7.97% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 5h 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 24, 2026